Accepted at 3:05 a.m. Nov, 01, 2023 by Aaron
Author: Aaron
Related Note: 1508366092584 1
Rationale for change

must be seropositive for IgG anti-toxoplasma antibodies

https://next.amboss.com/us/article/1o02aS#Z44dd1662b1b684d3304a52701d680821

Text Text
Extra
CD4 count (cells/μL)InfectionIndicationProphylaxis
<250CoccidioidomycosisReside in endemic area AND If (+) IgG or (+) IgMFluconazole
<200Pneumocystis pneumoniaEveryoneTMP-SMX
<100Toxoplasma gondiiPositive serologyTMP-SMX
<50Mycobacterium avium complexNo active infection + not on fully suppressive ARTAzithromycin OR clarithromycin
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy



Watch Trimethoprim/Sulfamethoxazole
Sketchy 2



Watch Antimicrobial Prophylaxis for AIDS Opportunistic Infections

Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo


Bootcamp
Watch associated Bootcamp video - Opportunistic Infections: Toxoplasmosis, Primary CNS Lymphoma, Cryptococcal Meningitis

Watch associated Bootcamp video - Antiparasitics : Pyrimethamine, Sulfadiazine, Nitroimidazoles, and Intraluminal Agents

Watch associated Bootcamp video - Positive-sense RNA Viruses : Secondary HIV-Associated Diseases
OME

Additional Resources
Empty field
One by one
Empty field
#AK_Original_Decks::Step_1::Lolnotacop::Drugs #AK_Step1_v12::#SketchyPharm::07_Antimicrobials::04_Other_Antibiotics::01_Trimethoprim/Sulfamethoxazole #AK_Step2_v12::#SketchyIM::09_Infectious_Disease::04_HIV_&_AIDS::02_Antimicrobial_prophylaxis_for_Opportunistic_Infections #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::20_Sulfonamides #AK_Step2_v12::#AMBOSS::IF0Yj3 #AK_Step2_v12::#UWorld::Step::17242 #AK_Step1_v12::#Bootcamp::Microbiology::28_Positive-sense_RNA_Viruses::22_Secondary_HIV-Associated_Diseases #AK_Step2_v12::#B&B::08_Infectious_Disease::02_Fungi_&_Parasites::03_Protozoal_Infections #AK_Step2_v12::#UWorld::COMLEX::103732 #AK_Step1_v12::#Bootcamp::Microbiology::38_Antiparasitics::01_Pyrimethamine_Sulfadiazine_Nitroimidazoles_and_Intraluminal_Agents #AK_Step2_v12::#B&B::08_Infectious_Disease::03_HIV::03_HIV_Complications #AK_Step2_v12::#SketchyIM::09_Infectious_Disease::Retired_Lessons::04_HIV_&_AIDS::03_AIDS_SOAP_[OLD_VERSION] #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::32_Antimicrobial_Prophylaxis #AK_Step1_v12::!FLAG_THESE_CARDS::PharmExtras_(topic_covered_by_micro) #AK_Step1_v12::#OME_banner #AK_Step1_v12::!FLAG_THESE_CARDS::Potential_duplicates !AK_UpdateTags::Step1decks::Lolnotacop::Drugs #AK_Step2_v12::#AMBOSS::nFa7im #AK_Step2_v12::#B&B::08_Infectious_Disease::03_HIV::01_HIV_Infection #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::33_Prophylaxis_in_HIV_Patients #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#Bootcamp::Microbiology::35_Opportunistic_Infections::05_Toxoplasmosis,_Primary_CNS_Lymphoma,_Cryptococcal_Meningitis #AK_Step1_v12::#Physeo::06_Micro::05_Viruses::14_Human_Immunodeficiency_Virus_(HIV) #AK_Step1_v12::#Physeo::09_Pharm::05_Antibiotics::18_Trimethoprim_&_Sulfonamides